Results 361 to 370 of about 315,545 (404)

Rapamycin (sirolimus, rapamune)

Current Opinion in Nephrology and Hypertension, 1995
Rapamycin is a novel immunosuppressive agent that is undergoing clinical trials for use in allograft rejection therapy. This paper reviews its in-vitro biological properties, the current state of knowledge concerning its mechanism of action, and its therapeutic applications.
S N, Sehgal, J S, Camardo, J A, Scarola, B T, Maida   +3 more
openaire   +2 more sources

IMMUNOPHARMACOLOGY OF RAPAMYCIN

Annual Review of Immunology, 1996
▪ Abstract  The potent immunosuppressive drugs FK506 and rapamycin interfere with signal transduction pathways required for T cell activation and growth. The distinct inhibitory effects of these drugs on the T cell activation program are mediated through the formation of pharmacologically active complexes with members of a family of intracellular ...
R T, Abraham, G J, Wiederrecht
openaire   +2 more sources

Blood distribution of rapamycin

Clinical Biochemistry, 1993
Rapamycin (RAPA) is a potent new immunosuppressive drug. Although blood concentration monitoring of RAPA is being performed in preclinical and clinical trials, little is known regarding the blood distribution of the drug. Such information would have an impact on the medium used for analysis of the drug.
R, Yatscoff, D, LeGatt, R, Keenan, P, Chackowsky   +3 more
openaire   +2 more sources

Rapamycin in cardiovascular medicine

Internal Medicine Journal, 2003
Abstract The cellular action of rapamycin (sirolimus), a natural fermentation product produced by Strepto­myces hygroscopicus, is mediated by binding to the FK506 binding protein. By inhibiting a kinase known as the target of rapamycin, it restricts the proliferation of smooth‐muscle cells by blocking cell‐cycle progression at the G1/S transition.The ...
Ruygrok, PN, Muller, DW, Serruys, PWJC (Patrick)   +2 more
openaire   +3 more sources

Mammalian target of rapamycin

Seminars in Oncology, 2004
Targeted molecular therapeutics are tailored toward the genetic abnormalities that cause tumor progression. Modulation of certain signaling pathways that are aberrant in cancer cells has the potential to provide an effective, nontoxic approach to therapy in a broad range of cancers. Agents targeting BCR-ABL (imatinib mesylate [formerly known as STI-571]
Funda, Meric-Bernstam, Gordon B, Mills
openaire   +2 more sources

Rapamycin in Lung Transplantation

Transplantation Proceedings, 2005
Rapamycin (RAPA) is a powerful immunosuppressant that also acts as an antiproliferative, which, therefore, could be useful in the treatment and prevention of bronchiolitis obliterans (BOS) in lung transplant recipients. We sought to report our experiences with RAPA in lung transplant patients with BOS that has not responded to the administration of ...
R Laporta, Hernández, P Ussetti, Gil, C García, Gallo, A, de Pablo Gafas, M C Carreño, Hernández, M J Ferreiro, Alvarez   +5 more
openaire   +2 more sources

Rapamycin: Therapeutic range investigations

Clinical Biochemistry, 1993
R Yatscoff, N Kneteman, J Fryer
openaire   +1 more source

Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast

Science, 1991
J. Heitman, N. Movva, MN Hall
semanticscholar   +1 more source

A mammalian protein targeted by G1-arresting rapamycin–receptor complex

Nature, 1994
E. Brown, M. Albers, Tae Bum Shin, K. Ichikawa, Curtis T. Keith, William Arbuthnot Sir Lane, S. Schreiber   +6 more
semanticscholar   +1 more source

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

Signal Transduction and Targeted Therapy, 2023
Manoj Garg
exaly